No Cash Boost For Novartis From Sandoz Spin-Off
Swiss Major Did Not Receive Any Formal Bids For Unit
After a lengthy review, Novartis has confirmed Sandoz will be a publicly traded standalone company listed on the SIX Swiss Exchange, although CEO Vas Narasimhan says he will still consider bids for the division.
You may also be interested in...
Novartis On Its ‘US First’ Commercial Plan
US Innovative Medicines president Victor Bulto talked to Scrip about why the company is pivoting to a commercial strategy that prioritizes the US and what that means for developing and selling drugs.
Teva's New CEO Francis Takes Over A Steadier – Though Still Rocky – Organization
Teva announced the appointment of former Sandoz CEO Richard Francis as its next leader as Kare Schultz steps down.
Novartis Changing Of The Guard Continues As R&D Chief Bradner Exits
A smooth handover hints at an amicable departure for Jay Bradner, but also gives CEO Vas Narasimhan the chance to refresh strategy with a new team.